KR20240099427A - 신규한 단백질 - Google Patents

신규한 단백질 Download PDF

Info

Publication number
KR20240099427A
KR20240099427A KR1020247018665A KR20247018665A KR20240099427A KR 20240099427 A KR20240099427 A KR 20240099427A KR 1020247018665 A KR1020247018665 A KR 1020247018665A KR 20247018665 A KR20247018665 A KR 20247018665A KR 20240099427 A KR20240099427 A KR 20240099427A
Authority
KR
South Korea
Prior art keywords
protein
fusion protein
polypeptide
disease
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247018665A
Other languages
English (en)
Korean (ko)
Inventor
레베카 애시필드
필립 헉슬리
Original Assignee
두센티스 바이오테라퓨틱스 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 두센티스 바이오테라퓨틱스 리미티드 filed Critical 두센티스 바이오테라퓨틱스 리미티드
Publication of KR20240099427A publication Critical patent/KR20240099427A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020247018665A 2021-11-03 2022-11-03 신규한 단백질 Pending KR20240099427A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB2115803.5 2021-11-03
GBGB2115803.5A GB202115803D0 (en) 2021-11-03 2021-11-03 Novel proteins
PCT/GB2022/052764 WO2023079278A1 (en) 2021-11-03 2022-11-03 Novel proteins

Publications (1)

Publication Number Publication Date
KR20240099427A true KR20240099427A (ko) 2024-06-28

Family

ID=78828504

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247018665A Pending KR20240099427A (ko) 2021-11-03 2022-11-03 신규한 단백질

Country Status (10)

Country Link
US (1) US20250026805A1 (cg-RX-API-DMAC7.html)
EP (1) EP4426719A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024542096A (cg-RX-API-DMAC7.html)
KR (1) KR20240099427A (cg-RX-API-DMAC7.html)
CN (1) CN118369334A (cg-RX-API-DMAC7.html)
AU (1) AU2022381844A1 (cg-RX-API-DMAC7.html)
CA (1) CA3236737A1 (cg-RX-API-DMAC7.html)
GB (1) GB202115803D0 (cg-RX-API-DMAC7.html)
IL (1) IL312470A (cg-RX-API-DMAC7.html)
WO (1) WO2023079278A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2626300A (en) * 2022-12-08 2024-07-24 Ducentis Biotherapeutics Ltd Mutated CD200 proteins and methods of use therof
GB202306711D0 (en) * 2023-05-05 2023-06-21 Ducentis Biotherapeutics Ltd Novel proteins

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5637481A (en) 1993-02-01 1997-06-10 Bristol-Myers Squibb Company Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
DE69226871T3 (de) 1991-06-27 2009-09-24 Bristol-Myers Squibb Co. CTL4A-Rezeptor, ihn enthaltenden Fusionsproteine und deren Verwendung
EP1171154A2 (en) 1999-04-13 2002-01-16 Schering Corporation Uses of mammalian ox2 protein and related reagents
WO2008089022A2 (en) 2007-01-11 2008-07-24 Boehringer Ingelheim International Gmbh Cd200 and its receptor, cd200r, modulate bone mass via the differentiation of osteoclasts
GB201608197D0 (en) * 2016-05-10 2016-06-22 Ducentis Biotherapeutics Ltd Novel proteins

Also Published As

Publication number Publication date
WO2023079278A1 (en) 2023-05-11
IL312470A (en) 2024-06-01
EP4426719A1 (en) 2024-09-11
CA3236737A1 (en) 2023-05-11
GB202115803D0 (en) 2021-12-15
JP2024542096A (ja) 2024-11-13
CN118369334A (zh) 2024-07-19
US20250026805A1 (en) 2025-01-23
AU2022381844A1 (en) 2024-06-06

Similar Documents

Publication Publication Date Title
KR102689460B1 (ko) Cd200 돌연변이체 및 그의 용도
US12173046B2 (en) TNFR2 agonists with improved stability
KR20160130463A (ko) 다량체 Fc 단백질
US20250026805A1 (en) Novel proteins
US20260116946A1 (en) Novel cd200 fusion proteins
KR20260007620A (ko) Cd200 융합 단백질
US20260116951A1 (en) Novel cd200 fusion proteins
JP7829127B2 (ja) 抗原結合ドメインおよびサイトカイン三量体ドメインを含む融合タンパク質
HK40072147B (en) Tnfr2 agonists with improved stability
HK40072147A (en) Tnfr2 agonists with improved stability
EA042608B1 (ru) Мутант cd200 и его применения

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000